Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user - Global Forecast to 2029

Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user—Global Forecast to 2029

The tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the tissue diagnostics market is attributed to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Additionally, emerging economies, growing developments in personalized medicines, and the shift towards automation are likely to offer significant growth opportunities for the tissue diagnostics market.

Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. The key factors attributing to the large market share of this segment are the repetitive need for consumables and technological advances in developing novel consumables. For instance, in May 2022, Qiagen N.V. (Netherlands) launched its therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis. It detects all the currently known activating and resistance EGFR mutations.

Based on technology, in 2022, the immunohistochemistry segment is expected to account for the largest share of the market. Immunohistochemistry provides variations between different types of tumors over conventional enzyme staining techniques; thus, the adoption of IHC for conducting immunodiagnostics tests and point-of-care diagnostic tests for tissue diagnostics is high. This contributes to the large market share of this segment.

Based on application, the tissue diagnostics market is segmented into breast cancer, lung cancer, colorectal and gastrointestinal cancer, prostate cancer, lymphatic cancer, and others. In 2022, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high prevalence of breast cancer and the presence of several research and screening programs. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced USD 47.5 million in funding to support breast cancer research during 2021-22.

Based on end user, in 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The rising prevalence of cancer globally and the subsequent high inflow of patients to hospitals and reference laboratories support the large market share of this segment.

An in-depth analysis of the geographical scenario of the tissue diagnostics market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to account for the largest share of the tissue diagnostics market. The high incidence rate of cancer, access to a number of public programs to minimize cancer incidence, technological advancements, and the adoption of personalized medicine attribute to the large market share of this regional market.

Some of the key players operating in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Sigma-Aldrich Co. LLC) (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (U.K.), Becton, Dickinson, and Company (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories, Inc. (U.S.), Bio SB, INC (U.S.), 3DHISTECH Ltd. (Hungary), and HOLOGIC, INC. (U.S.).

Scope of the Report:


Global Tissue Diagnostics Market, by Product Type

Consumables
Antibodies
Kits
Reagents
Instruments
Slide Staining Systems
Slide Scanners
Tissue Processors

Other Instruments

Note: Other instruments include microarrays and embedding systems.

Global Tissue Diagnostics Market, by Technology
Immunohistochemistry (IHC)
In-situ Hybridization (ISH)
Digital Pathology
H&E Slide Staining
ther Technologies

Note: Other technologies include molecular, immunofluorescence, and special staining

Global Tissue Diagnostics Market, by Application
Breast Cancer
Lung Cancer
Colorectal and Gastrointestinal Cancer
Prostate Cancer
Lymphatic Cancer
ther Applications

Note: Other applications include cervical cancer, melanoma, lip, oral cavity cancer

Global Tissue Diagnostics Market, by End User
Hospitals and Reference Laboratories
Research Institutes
Pharmaceutical Companies
Contract Research Organization

Global Tissue Diagnostics Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Tissue Diagnostics Market - Report Summary

Report Metrics	Details
Years Considered	2020 - 2029
Base Year	2021
Forecast Period	2022-2029
Page Count	226
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Product Type, Technique, Application, and End User
Regions Covered	North America (The United States, Mexico, Canada), Europe (Germany, France, Spain, and The United Kingdom), Asia (China, Japan, India, Indonesia, and South Korea), and ROW (Brazil, Argentina)
Key Companies Mentioned	F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories (U.S.), Bio SB, INC (U.S.), 3DHISTECH (Hungary), and HOLOGIC, INC. (U.S.)

FAQs About the Report

What is the focus of the global tissue diagnostics market?

This study offers a detailed assessment of the tissue diagnostics market, including the market size & forecast for various segmentations such as product type, technique, application, and end user. This report also involves the value analysis of various segments and sub-segments of the tissue diagnostics market at the regional and country levels.

What is the value of revenue generated from tissue diagnostics across the globe? At what rate is their demand expected to grow for the next 5-7 years?

The global tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% during the forecast period.

Based on product type, which tissue diagnostics segment is expected to hold the largest share of the market in 2022?

Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. Consumables such as antibodies, kits & reagents are extensively and recurringly used daily, thus attributing to the large market share of this segment.

Which application segment is expected to account for the largest share of the market?

Based on application, in 2022, the breast cancer segment is expected to account for the largest share of the market. The high prevalence of breast cancer and the presence of early breast cancer screening programs are the factors attributing to the large market share of this segment.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global tissue diagnostics market?

The growth of this market is attributed to the global rise in cancer prevalence and the increasing clinical trials for oncology drugs. Along with this, the rising focus on personalized healthcare, the advent of digital pathology, and the automation of tissue diagnosis are the major opportunities for existing market players and new entrants in the global tissue diagnostics market

Who are the major players operating in the global tissue diagnostics market?

The key players operating in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Abcam plc (U.K.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories (U.S.), Bio SB, INC (U.S.), 3DHISTECH (Hungary), and HOLOGIC, INC. (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the market players operating in the global tissue diagnostics market?

Emerging economies in Asia-Pacific are projected to offer significant growth opportunities to the market players due to the growing cancer prevalence, the rising spending on healthcare, and the improving adoption of advanced technologies for cancer diagnostics.